Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abeona TherapeuticsABEO +2.90%32 EBITDA Margin % is -176.31% as of Mar. 2026. GuruFocus rates ABEO with a GF Score™ of 32/100. The stock has 8 warning signs investors should review. Among 942 Biotechnology companies, Abeona Therapeutics ranks better than 99.04% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Abeona Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-15.37 Mil. Abeona Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $8.72 Mil. Therefore, Abeona Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -176.31%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Abeona Therapeutics EBITDA Margin % Related Terms
Abeona Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Abeona Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABEO vs RCKT, UPB, PALI: EBITDA Margin % Comparison
For the Biotechnology subindustry, Abeona Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abeona Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Abeona Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics (ABEO) has a EBITDA Margin % of -176.31% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abeona Therapeutics and its competitors. According to the industry distribution chart, Abeona Therapeutics ranks #9 out of 942 companies in the Biotechnology industry, placing it in the top 1%.
Is Abeona Therapeutics' EBITDA Margin % too high?
Abeona Therapeutics' current EBITDA Margin % is -176.31%. Based on the distribution chart, Abeona Therapeutics ranks #9 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abeona Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' EBITDA Margin % compare to RCKT and UPB?
According to the Biotechnology industry distribution chart, Abeona Therapeutics ranks #9 out of 942 companies for EBITDA Margin %. This places Abeona Therapeutics in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abeona Therapeutics and its competitors. Abeona Therapeutics's current EBITDA Margin % is -176.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Abeona Therapeutics (ABEO) has a current EBITDA Margin % of -176.31%. The current EBITDA Margin % is -176.31%. Abeona Therapeutics' overall GF Score™ is 32/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Abeona Therapeutics (ABEO), the current EBITDA Margin % is -176.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
32GF Score
Get the complete analysis for ABEO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABEO has been successfully added to your 
